Loading company…
Zhongji Zhiyao develops gene therapy drugs for single-gene disorders, including RDEB and ß-Mediterranean Anemia.
Based in Nanjing, China, the company conducts research, production, and sales of gene therapy drugs. Its work includes treatments for RDEB and ß-Mediterranean Anemia using gene therapy and AAV vectors. In June 2025, it raised Series B funding from Botong Venture Capital and Zhuhai Hengqin Kangyuan Huiying Investment Management Co., Ltd.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign inWork at Zhongji Zhiyao (Nanjing) Biotechnology Co., Ltd.? This is my company